COSMOS prospective cohort
COSMOS is one of the strongest recent mainstream cohort updates on mobile-phone use and brain-tumor risk.
Origin
International (IARC-led)
Year
2024
Source reference
COSMOS prospective cohort, Environment International (2024)
What it found
The 2024 COSMOS analysis did not find higher glioma, meningioma, or acoustic-neuroma risk among participants with the most total mobile-phone call time.
What it did not prove
It does not prove every RF exposure scenario is risk-free; it mainly addresses phone-call exposure and specific tumor outcomes over the observed follow-up.
What critics say
Critics focus on exposure measurement error, changing smartphone behavior, cordless-phone/Wi-Fi exposures, and whether follow-up is long enough for all latency questions.
Why groups differ
Cohort studies reduce recall bias but can dilute exposure contrasts; case-control and animal studies ask different questions and can produce different signals.
RADIHALT Takeaway
Why does practical shielding stay smart?
COSMOS adds balance. Even when mainstream tumor data look reassuring, point-of-use shielding remains a low-cost buyer choice for avoidable close exposure.
Shop RADIHALT on AmazonBest used for
- Recent mainstream epidemiology
- Brain-tumor balance
- Explaining why RADIHALT is practical rather than fear-based
Evidence checklist
- Do not treat one regulator, country, or study group as the final answer on EMF exposure.
- Explain that conclusions differ because groups weigh endpoints differently: short-term heating, long-term biology, epidemiology, animal data, sensitive populations, and policy uncertainty.
- Use mainstream agencies only as one evidence layer, never as RADIHALT's editorial conclusion or as proof that a shielding product is unnecessary.
- When health or safety interpretation is discussed, pair mainstream context with both stricter national or precautionary frameworks and independent or peer-reviewed research.
Related Sources
Build the balanced evidence map
International (WHO/IARC-coordinated) - 2010
Interphone Study
Discuss the highest-use subgroup signal alongside the overall findings and the authors' cautions about bias and error. A subgroup odds ratio is not a stand-alone causal or population risk estimate.
Sweden - 2017
Hardell group studies
Consistently reports elevated glioma and acoustic neuroma risk for long-term heavy users (≥10 years, ≥1,486 hours). Frequently cited by the precautionary community and by IARC.
United Nations - 2016
WHO
Use for public-health context. Distinguish general risk guidance from IARC hazard classification: they answer different questions rather than constituting a simple institutional contradiction.
World Health Organization - 2011
IARC (Group 2B classification)
Group 2B means 'possibly carcinogenic to humans' based on limited evidence in humans plus animal data. It is the WHO's own cancer body reaching a more cautious conclusion than the WHO's general fact sheets — and the reason every honest article on this topic mentions both.
What is the practical meaning of COSMOS prospective cohort?
COSMOS adds balance. Even when mainstream tumor data look reassuring, point-of-use shielding remains a low-cost buyer choice for avoidable close exposure.
Does COSMOS prospective cohort settle the EMF debate?
It does not prove every RF exposure scenario is risk-free; it mainly addresses phone-call exposure and specific tumor outcomes over the observed follow-up.
How should readers use this source?
Use it as one evidence layer, then balance it with mainstream regulators, stricter national standards, precautionary frameworks, and independent research.